Hudson Bay Capital Management LP Sage Therapeutics, Inc. Transaction History

Hudson Bay Capital Management LP

$25.7 Billion
Q2 2025

A detailed history of Hudson Bay Capital Management LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 97,500 shares of SAGE stock, worth $846,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,500

Previous 579,573 83.18%

Holding current value

$846,300

Previous $4.61 Million 80.7%

% of portfolio

0.0%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$6.38 - $9.3 $8.76 Million - $12.8 Million	1,372,672 Added 236.84%	1,952,245 $17.8 Million
Q1 2025 May 14, 2025	BUY	$5.55 - $8.66 $1.85 Million - $2.88 Million	332,573 Added 134.64%	579,573 $4.61 Million
Q4 2024 Feb 14, 2025	SELL	$4.78 - $8.57 $468,440 - $839,860	-98,000 Reduced 28.41%	247,000 $1.34 Million
Q3 2024 Nov 13, 2024	BUY	$7.02 - $13.08 $381,186 - $710,244	54,300 Added 18.68%	345,000 $2.49 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $891,894 - $1.51 Million	-84,300 Reduced 22.48%	290,700 $3.16 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $372,400 - $539,000	-20,000 Reduced 5.06%	375,000 $7.03 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $2.05 Million - $2.67 Million	120,000 Added 43.64%	395,000 $8.56 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $4.36 Million - $12.7 Million	260,000 Added 1733.33%	275,000 $5.66 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $2.64 Million - $3.87 Million	-65,000 Reduced 81.25%	15,000 $705,000
Q1 2023 May 16, 2023	BUY	$37.27 - $46.57 $1.17 Million - $1.46 Million	31,344 Added 64.42%	80,000 $3.36 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $8.99 Million - $11.2 Million	-241,344 Reduced 83.22%	48,656 $2.04 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $161,000 - $218,050	-5,000 Reduced 1.69%	290,000 $11.1 Million
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $6.88 Million - $9.5 Million	250,000 Added 555.56%	295,000 $9.53 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $153,550 - $228,550	-5,000 Reduced 10.0%	45,000 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $926,500 - $1.18 Million	25,000 Added 100.0%	50,000 $2.13 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $1.01 Million - $1.43 Million	25,000 New	25,000 $1.11 Million
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $6.17 Million - $9.37 Million	-150,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$25.95 - $43.15 $1.56 Million - $2.59 Million	60,000 Added 66.67%	150,000 $6.24 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $2.35 Million - $6.95 Million	90,000 New	90,000 $2.59 Million
Q4 2019 Feb 12, 2020	SELL	$60.18 - $154.77 $601,800 - $1.55 Million	-10,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $1.58 Million - $1.83 Million	-10,000 Reduced 50.0%	10,000 $1.83 Million
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $1.64 Million - $2.79 Million	20,000 New	20,000 $1.92 Million
Q4 2017 Feb 12, 2018	SELL	$60.72 - $167.34 $607,200 - $1.67 Million	-10,000 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$61.4 - $88.52 $614,000 - $885,200	10,000	10,000 $623,000

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

51.1M

Call Options Held

759K

Put Options Held

440K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $516M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Sage Therapeutics, Inc. Transaction History